- The Dish’s Weekly Biotechnology News Wrap Up – March 24, 2017Posted 3 days ago
- Laminin cell culture matrices – The key to efficient derivation and reliable culture of stem cells and specialized cells lies within these extracellular matrix proteinsPosted 4 days ago
- Video – Fortem: A platform film built for bioprocessPosted 5 days ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 17, 2017Posted 1 week ago
- Cool Tool – The Human Protein AtlasPosted 2 weeks ago
- Optimization of Roche Liberase MNP-S GMP Grade in the Enzymatic Digestion of Human Umbilical Cord for the Isolation of Mesenchymal Stem CellsPosted 2 weeks ago
- Ask the Expert – Maximizing Transient Protein ProductionPosted 2 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 10, 2017Posted 2 weeks ago
- Enabling Viral Vector Production and Vaccine Manufacturing using the iCELLis – a single-use, automated, and closed manufacturing platformPosted 3 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 3, 2017Posted 3 weeks ago
Ask the Expert: Options for Increasing Output and Reducing Footprint in Adherent Cell Culture
Adherent cell culture is often used in the manufacture of biologic products, including vaccines. Historically, the surface for cells to adhere to has been provided either by a two-dimensional (2D) system such as roller bottles, T-flasks, cell factories or cell stacks; or microcarrier beads within a traditional stirred tank bioreactor. However the need to increase product production and reduce manufacturing footprints have led to the creation of novel solutions.
One alternative solution to traditional 2D systems and to a microcarrier-stirred tank option is a fixed-bed disposable bioreactor, which can provide efficient scale-up and manufacturing with a small footprint.
Join Jose Castillo, Director of Cell Culture Technologies for Pall Life Sciences, to explore various options for utilizing fixed-bed bioreactors in adherent cell culture.
Jose Castillo transitioned into his role as Director of Cell Culture Technologies for Pall Life Sciences during the December 2013 acquisition of ATMI LifeSciences. Before this time, Jose was one of the original founders and acting CTO at Artelis, which ATMI LifeSciences acquired in November 2010. Throughout his career, Jose has been heavily entrenched in development aspects for “process intensification” in disposable bioreactors and related processes for vaccine and antibody applications, as well as for the expansion of stem cells.
Prior to founding Artelis, Jose worked as the Manager of Viral Vaccine Industrialization for GSK Biologicals. He has a general background in Chemical Engineering, including a PhD in Applied Sciences from the Université libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.
Don’t miss this chance to have your adherent cell culture questions answered!